---
title: "This LSD-Based Drug Just Scored Again. Definium Stock Soars."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295674953.md"
description: "Definium Therapeutics recently announced the successful completion of the second out of two favorable Phase 3 trials for its LSD-derived medication. Following this news, the biotech company's stock saw a significant increase in value. This achievement marks a significant turning point for the company and has generated positive attention from investors."
datetime: "2026-08-12T13:33:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295674953.md)
  - [en](https://longbridge.com/en/news/295674953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295674953.md)
---

# This LSD-Based Drug Just Scored Again. Definium Stock Soars.

Definium Therapeutics recently announced the successful completion of the second out of two favorable Phase 3 trials for its LSD-derived medication. Following this news, the biotech company's stock saw a significant increase in value. This achievement marks a significant turning point for the company and has generated positive attention from investors.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [Definium says LSD-based pill reduces anxiety in late-stage study](https://longbridge.com/en/news/295653550.md)
- [Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'](https://longbridge.com/en/news/295680444.md)
- [Will Strong Phase 3 Depression Data and Q2 Review Webcast Change Definium Therapeutics' (DFTX) Narrative](https://longbridge.com/en/news/294588855.md)
- [Is Definium Therapeutics (DFTX) Expensive As New GAD Study Sharpens Its Late Stage Case?](https://longbridge.com/en/news/293649367.md)
- [Definium Therapeutics Sets $805 Million Public Offering at $34; Underwriting Agreement Signed](https://longbridge.com/en/news/290742592.md)